Related Experiment Video
Updated: May 11, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Determination of APTT factor sensitivity--the misguiding guideline
A S Lawrie1, S Kitchen, M Efthymiou
1Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
Introduction:
The Clinical and Laboratory Standards Institute (CLSI) has produced a guideline detailing how to determine the activated partial thromboplastin time's (APTT) sensitivity to clotting factor deficiencies, by mixing normal and deficient plasmas. Using the guideline, we determined the factor sensitivity of two APTT reagents.
Methods:
APTTs were performed using Actin FS and Actin FSL on a Sysmex CS-5100 analyser. The quality of factor-deficient and reference plasmas from three commercial sources was assessed by assaying each of the clotting factors within the plasmas and by performing thrombin generation tests (TGT).
Results:
Testing samples from 50 normal healthy subjects gave a two-standard deviation range of 21.8-29.2 s for Actin FS and 23.5-29.3 s for Actin FSL. The upper limits of these ranges were subsequently used to determine APTT factor sensitivity. Assay of factor levels within the deficient plasmas demonstrated that they were specifically deficient in a single factor, with most other factors in the range 50-150 iu/dL (Technoclone factor VII-deficient plasma has 26 iu/dL factor IX). APTTs performed on mixtures of normal and deficient plasmas gave diverse sensitivity to factor deficiencies dependent on the sources of deficient plasma. TGT studies on the deficient plasmas revealed that the potential to generate thrombin was not solely associated with the levels of their component clotting factors.
Conclusion:
Determination of APTT factor sensitivity in accordance with the CLSI guideline can give inconsistent and misleading results.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Therapeutic Drug Monitoring: Affecting Factors
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

